**Bryn Pharma Bolsters Executive Lineup to Drive Needle-Free Epinephrine Innovation Toward Market Launch**

The race to revolutionize anaphylaxis treatment just got serious. Bryn Pharma has tapped three seasoned pharma veterans to accelerate commercialization of UTULY™, its groundbreaking intranasal epinephrine spray designed to replace traditional needle-based delivery systems. The timing couldn't be more critical—the company is gearing up for FDA clearance and market entry of what could redefine how millions of allergy sufferers prepare for life-threatening reactions.

**Strategic Leadership Meets Patient-Centric Innovation**

Heading the strategy charge is Nurry Hong, now Chief Strategy and Business Development Officer. With over two decades in life sciences and biotech, Hong brings credible pedigree in the food allergy space. His previous roles included CEO of Pareto Bio and Chief of Strategy at FARE, the nation's largest food allergy nonprofit. More importantly, Hong is a patient advocate himself—a father navigating his son's multiple food allergies—which injects authentic mission-driven leadership into Bryn's boardroom.

Supporting Hong is Steve Killmeyer, appointed as Chief Financial Officer. Killmeyer arrives with 15+ years of experience across pharma, biotech, and medical devices. He previously shaped financial strategy at Aimmune Therapeutics (Nestle's pharma arm) and spent five years in Pfizer and Johnson & Johnson M&A advisory at Deloitte. His background in healthcare private equity and investment banking at Merrill Lynch rounds out a profile engineered for scaling early-stage breakthroughs into market-ready enterprises.

Completing the trio is Lisa Lucifero, VP and Head of Human Resources. Lucifero brings global HR leadership credentials from DBV Technologies, Mallinckrodt Pharmaceuticals, and Sanofi. Her focus on talent acquisition, organizational design, and change management positions her to build the infrastructure Bryn needs as it transitions from development to commercialization phase.

**Board Gets a Financial Heavyweight**

Michael Kaseta, currently CFO of Liquidia Corporation (Nasdaq: LQKA), joins Bryn's Board of Directors. Kaseta's track record includes CFO roles at Aerami Therapeutics and Aralez Pharmaceuticals, plus significant tenure at Sanofi managing finance across North America operations. His appointment signals serious growth ambitions and financial rigor.

**Why This Matters for the Allergy Community**

Bryn Pharma was founded in 2017 by patients, for patients—explicitly built to disrupt the epinephrine autoinjector market with something faster, easier, and more accessible. UTULY™ represents a genuinely different approach: intranasal administration that bypasses needles while delivering rapid epinephrine uptake. As the food allergy population grows and existing devices face usability and cost barriers, this leadership reshuffle suggests Bryn is ready to compete at scale.

The combination of Hong's strategic vision, Killmeyer's financial discipline, and Lucifero's operational infrastructure—bolstered by Kaseta's board-level oversight—constructs a leadership model built for the critical phase ahead. For a company preparing to enter one of pharma's most competitive therapeutic areas, that's not just executive hiring. That's momentum.